IFM Investors Pty Ltd Acquires 1,508 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• IFM Investors Pty Ltd increased its stake in Alnylam Pharmaceuticals by 6.3% during the second quarter, bringing its total holdings to 25,358 shares valued at approximately $8.27 million.
• Insider transactions revealed that executives Kevin Joseph Fitzgerald and Pushkal Garg sold shares worth a combined $1.3 million, resulting in a decrease in their ownership percentages.
• Alnylam Pharmaceuticals reported better-than-expected quarterly earnings with an EPS of $0.32, surpassing analyst estimates of ($0.54), and achieved a revenue of $773.69 million, which is up 17.3% year-over-year.

IFM Investors Pty Ltd boosted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 6.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,358 shares of the biopharmaceutical company's stock after acquiring an additional 1,508 shares during the period. IFM Investors Pty Ltd's holdings in Alnylam Pharmaceuticals were worth $8,269,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in Alnylam Pharmaceuticals by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company's stock valued at $3,525,544,000 after acquiring an additional 323,206 shares during the period. T. Rowe Price Investment Management Inc. lifted its position in Alnylam Pharmaceuticals by 0.8% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company's stock valued at $1,192,988,000 after acquiring an additional 33,696 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Alnylam Pharmaceuticals by 5.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company's stock valued at $946,466,000 after acquiring an additional 185,783 shares during the period. American Century Companies Inc. lifted its position in Alnylam Pharmaceuticals by 9.8% during the 1st quarter. American Century Companies Inc. now owns 1,760,435 shares of the biopharmaceutical company's stock valued at $475,353,000 after acquiring an additional 156,411 shares during the period. Finally, Orbis Allan Gray Ltd lifted its position in Alnylam Pharmaceuticals by 11.0% during the 1st quarter. Orbis Allan Gray Ltd now owns 1,634,923 shares of the biopharmaceutical company's stock valued at $441,462,000 after acquiring an additional 162,121 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Down 0.7%

Alnylam Pharmaceuticals stock traded down $3.19 during trading hours on Tuesday, hitting $455.73. The stock had a trading volume of 349,387 shares, compared to its average volume of 976,988. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. The stock has a market capitalization of $59.74 billion, a P/E ratio of -184.36 and a beta of 0.32. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $484.21. The stock's 50-day moving average price is $417.91 and its 200-day moving average price is $326.74.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm had revenue of $773.69 million during the quarter, compared to analysts' expectations of $633.54 million. During the same period in the previous year, the company earned ($0.13) earnings per share. The firm's quarterly revenue was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Activity

In other news, Director Colleen F. Reitan sold 18,000 shares of the business's stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $467.60, for a total transaction of $8,416,800.00. Following the completion of the transaction, the director directly owned 775 shares of the company's stock, valued at $362,390. The trade was a 95.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael W. Bonney sold 11,250 shares of the business's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $450.00, for a total transaction of $5,062,500.00. Following the transaction, the director directly owned 16,804 shares of the company's stock, valued at $7,561,800. The trade was a 40.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 75,594 shares of company stock valued at $33,968,256 over the last three months. Corporate insiders own 1.20% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Citigroup lifted their price target on shares of Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the company a "buy" rating in a research report on Tuesday, September 2nd. Needham & Company LLC lifted their price target on shares of Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the company a "buy" rating in a research report on Thursday, July 31st. Piper Sandler lifted their target price on shares of Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the stock an "overweight" rating in a report on Friday, August 1st. UBS Group lifted their target price on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Finally, Oppenheimer raised shares of Alnylam Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $490.00 target price for the company in a report on Monday, August 4th. Twenty-four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $439.58.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.